The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …

Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As (III)
and As (V). As (III), in particular, reacts with closely spaced protein thiols, forming stable …

Purpose To determine the activity of decitabine, a DNA methylation inhibitor, in imatinib-
refractory or intolerant chronic myelogenous leukemia. Materials and Methods Thirty-five …

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a
specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene …

Chronic myelogenous leukemia (CML) results from malignant transformation of a primitive
hematopoietic cell by the BCR/ABL oncogene. The breakpoint cluster region/ABL …

Abstract Purpose: 1-β-d-Arabinofuranosylcytosine (cytarabine; ara-C) is the most active
agent in myeloid leukemia. 5-Aza-2′-deoxycytidine (DAC) is a cytosine analogue that …

Ovarian cancer is the most lethal of all gynecologic neoplasms. Early-stage malignancy is
frequently asymptomatic and difficult to detect and thus, by the time of diagnosis, most …

Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that
specifically inhibits the BCR–ABL tyrosine kinase activity in patients with Philadelphia …